- Nachrichtendetail
-
01.07.2024 08:00:31 - dpa-AFX: EQS-News: Partners Group to acquire majority stake in FairJourney Biologics, a leading antibody discovery Contract Research Organization (english)
Partners Group to acquire majority stake in FairJourney Biologics, a leading
antibody discovery Contract Research Organization
Partners Group / Key word(s): Acquisition/Investment
Partners Group to acquire majority stake in FairJourney Biologics, a leading
antibody discovery Contract Research Organization
01.07.2024 / 08:00 CET/CEST
---------------------------------------------------------------------------
Baar-Zug, Switzerland; 1 July 2024
Partners Group, one of the largest firms in the global private markets
industry, has agreed, on behalf of its clients, to acquire a majority stake
in FairJourney Biologics ("FairJourney" or "the Company"), a leading
antibody discovery Contract Research Organization ("CRO"), from GHO Capital
Partners ("GHO Capital").
Founded in 2012 and headquartered in Porto, Portugal, FairJourney is a CRO
supporting pharmaceutical and biotech companies working at the cutting edge
of innovation to develop the next generation of antibody-based therapies.
The Company provides services for the discovery, engineering, production,
and characterization of antibodies. FairJourney has worked with over 250
clients across the globe to develop more than 4,000 unique screening
libraries for identifying antibodies. The Company's partnerships have
yielded 14 therapies that are currently in active clinical development to
treat unmet patient needs across oncology, immunology, and cardiovascular
disease. FairJourney has demonstrated market leading success rates and
outcomes driven by the quality of its people and advanced technologies,
supported by state-of-the-art operations in Porto and Cambridge, UK.
FairJourney is set to benefit from structural tailwinds driving growth in
the market for antibody discovery. This includes higher R&D spending by the
pharmaceutical industry, increased outsourcing to specialized innovation
partners, the established track record of antibody-based therapies, and a
favorable regulatory landscape.
Partners Group will work with founder António Parada, who will remain a
significant shareholder, and his management team on a value creation plan
for FairJourney that will expand its technology and capabilities through
organic and inorganic investment to unlock faster, more effective drug
development for its partners. The transaction will also see a meaningful
reinvestment from GHO Capital.
Pascal Noth, Head of Private Equity Health & Life Europe, Partners Group,
says: "FairJourney is a high-quality leader in antibody development. We look
forward to investing into further broadening its capabilities in
pre-clinical R&D and in silico design and partnering with young teams around
the world that are pushing the edge of scientific technologies, as the team
in Porto and Cambridge have done successfully in the past. We also look
forward to partnering with the FairJourney management team as well as
existing investor GHO Capital, a specialist investor in global healthcare
with partners who share our strategy of supporting companies that drive the
development of innovative medicines to transform patient lives."
António Parada, Founder and Chief Executive Officer, FairJourney Biologics,
comments: "We have sought to build end-to-end capabilities that drive
differentiated results for our partners. We look forward to working with our
new majority shareholder Partners Group, which is well positioned to expand
our technologies and offering at a global scale, and GHO Capital."
Jean Ghabache, Member of Management, Private Equity Health & Life, Partners
Group, adds: "FairJourney serves at the intersection of several highly
thematic growth trends in pharmaceutical R&D. The Company has built a strong
operational engine underpinned by leading technology and excellence in
project delivery. We see FairJourney as a platform to lead innovation in
next-generation biologics medicines."
Partners Group has USD 76 billion in private equity assets under management.
The firm's Private Equity Health & Life vertical has over 40 professionals
globally that track different sectors for years through deep thematic
research. The vertical has made over 30 direct investments, including PCI
Pharma Services, a provider of pharmaceutical supply chain solutions, and
Pharmathen, a developer and manufacturer of drug delivery technologies.
Partners Group was advised by Ropes & Gray (legal), PwC (financial and tax),
and Larka (commercial) on the transaction.
About Partners Group
Partners Group is one of the largest firms in the global private markets
industry, with 1'900 professionals and approximately USD 150 billion in
assets under management. The firm has investment programs and custom
mandates spanning private equity, private credit, infrastructure, real
estate, and royalties. With its heritage in Switzerland and primary presence
in the Americas in Colorado, Partners Group is built differently from the
rest of the industry. The firm leverages its differentiated culture and
operationally oriented approach to identify attractive investment themes and
to build businesses and assets into market leaders. For more information,
please visit www.partnersgroup.com or follow us on LinkedIn.
Media relations contact
Henry Weston
Phone: +44 207 575 2593
Email: henry.weston@partnersgroup.com
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
End of News EQS News Service
---------------------------------------------------------------------------
1936283 01.07.2024 CET/CEST
antibody discovery Contract Research Organization
Partners Group / Key word(s): Acquisition/Investment
Partners Group to acquire majority stake in FairJourney Biologics, a leading
antibody discovery Contract Research Organization
01.07.2024 / 08:00 CET/CEST
---------------------------------------------------------------------------
Baar-Zug, Switzerland; 1 July 2024
* FairJourney is a partner to pharmaceutical and biotech companies for the
discovery, production, and characterization of antibody-based therapies
* FairJourney is set to benefit from tailwinds in the antibody discovery
market, including higher pharmaceutical R&D spending and increased
outsourcing
* Partners Group's investment, alongside a minority reinvestment from GHO
Capital, will support FairJourney in accelerating growth
Partners Group, one of the largest firms in the global private markets
industry, has agreed, on behalf of its clients, to acquire a majority stake
in FairJourney Biologics ("FairJourney" or "the Company"), a leading
antibody discovery Contract Research Organization ("CRO"), from GHO Capital
Partners ("GHO Capital").
Founded in 2012 and headquartered in Porto, Portugal, FairJourney is a CRO
supporting pharmaceutical and biotech companies working at the cutting edge
of innovation to develop the next generation of antibody-based therapies.
The Company provides services for the discovery, engineering, production,
and characterization of antibodies. FairJourney has worked with over 250
clients across the globe to develop more than 4,000 unique screening
libraries for identifying antibodies. The Company's partnerships have
yielded 14 therapies that are currently in active clinical development to
treat unmet patient needs across oncology, immunology, and cardiovascular
disease. FairJourney has demonstrated market leading success rates and
outcomes driven by the quality of its people and advanced technologies,
supported by state-of-the-art operations in Porto and Cambridge, UK.
FairJourney is set to benefit from structural tailwinds driving growth in
the market for antibody discovery. This includes higher R&D spending by the
pharmaceutical industry, increased outsourcing to specialized innovation
partners, the established track record of antibody-based therapies, and a
favorable regulatory landscape.
Partners Group will work with founder António Parada, who will remain a
significant shareholder, and his management team on a value creation plan
for FairJourney that will expand its technology and capabilities through
organic and inorganic investment to unlock faster, more effective drug
development for its partners. The transaction will also see a meaningful
reinvestment from GHO Capital.
Pascal Noth, Head of Private Equity Health & Life Europe, Partners Group,
says: "FairJourney is a high-quality leader in antibody development. We look
forward to investing into further broadening its capabilities in
pre-clinical R&D and in silico design and partnering with young teams around
the world that are pushing the edge of scientific technologies, as the team
in Porto and Cambridge have done successfully in the past. We also look
forward to partnering with the FairJourney management team as well as
existing investor GHO Capital, a specialist investor in global healthcare
with partners who share our strategy of supporting companies that drive the
development of innovative medicines to transform patient lives."
António Parada, Founder and Chief Executive Officer, FairJourney Biologics,
comments: "We have sought to build end-to-end capabilities that drive
differentiated results for our partners. We look forward to working with our
new majority shareholder Partners Group, which is well positioned to expand
our technologies and offering at a global scale, and GHO Capital."
Jean Ghabache, Member of Management, Private Equity Health & Life, Partners
Group, adds: "FairJourney serves at the intersection of several highly
thematic growth trends in pharmaceutical R&D. The Company has built a strong
operational engine underpinned by leading technology and excellence in
project delivery. We see FairJourney as a platform to lead innovation in
next-generation biologics medicines."
Partners Group has USD 76 billion in private equity assets under management.
The firm's Private Equity Health & Life vertical has over 40 professionals
globally that track different sectors for years through deep thematic
research. The vertical has made over 30 direct investments, including PCI
Pharma Services, a provider of pharmaceutical supply chain solutions, and
Pharmathen, a developer and manufacturer of drug delivery technologies.
Partners Group was advised by Ropes & Gray (legal), PwC (financial and tax),
and Larka (commercial) on the transaction.
About Partners Group
Partners Group is one of the largest firms in the global private markets
industry, with 1'900 professionals and approximately USD 150 billion in
assets under management. The firm has investment programs and custom
mandates spanning private equity, private credit, infrastructure, real
estate, and royalties. With its heritage in Switzerland and primary presence
in the Americas in Colorado, Partners Group is built differently from the
rest of the industry. The firm leverages its differentiated culture and
operationally oriented approach to identify attractive investment themes and
to build businesses and assets into market leaders. For more information,
please visit www.partnersgroup.com or follow us on LinkedIn.
Media relations contact
Henry Weston
Phone: +44 207 575 2593
Email: henry.weston@partnersgroup.com
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
Language: English
Company: Partners Group
Zugerstrasse 57
6341 Baar
Switzerland
Phone: +41 41 784 60 00
Fax: + 41 41 784 60 01
E-mail: partnersgroup@partnersgroup.com
Internet: https://www.partnersgroup.com/en/
ISIN: CH0024608827
Valor: 2460882
Listed: SIX Swiss Exchange
EQS News ID: 1936283
End of News EQS News Service
---------------------------------------------------------------------------
1936283 01.07.2024 CET/CEST
